Evaxion announces changes to executive management to optimize the value of proprietary ai-immunology™ platform and portfolio

Copenhagen, denmark, july 1, 2025 - evaxion a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, announces several key executive management changes to optimize value from its proprietary ai-immunology™ platform and pipeline.
EVAX Ratings Summary
EVAX Quant Ranking